Insulin resistance, blood sugar regulation, metabolic syndrome, and body composition
461 articles
A newly discovered liver-to-gut communication pathway shows how fatty liver worsens hyperglycemia by hijacking intestinal stem cell behavior.
A completed Maastricht trial tests whether targeted protein and exercise can boost muscle protein synthesis before dialysis becomes necessary.
New research reveals FGF21 has a physiological role in reducing ER stress by amplifying the unfolded protein response through sulfide signaling.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
A Danish case-control trial uses gold-standard metabolic testing to uncover how mtDNA mutations impair muscle glucose uptake and drive insulin resistance.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
A completed OSU trial investigates whether short-term exercise training can restore impaired mitochondrial cleanup pathways in overweight and obese skeletal muscle.
Researchers test lipid, glucose, and mixed meal challenges to pinpoint optimal post-meal sample collection windows for future cardiovascular studies.
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
Scientists identify an NADH-dependent molecular switch linking glycolysis to mitochondrial ATP synthesis, revealing a new metabolic control point.
